Skip To Main Content
Sònia Gatius on Muck Rack

Sònia Gatius

As seen in: Nature, MDPI, European Journal of Cancer
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Sònia

Contact Sònia, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

ARID1A deficiency reprograms the tumor secretome, enhancing microenvironmental remodeling and metastatic dissemination in endometrial carcinoma

|
By Cristina Megino-Luque, Manel Albertí-Valls, Sara Olave, Nuria Bonifaci, Anna Formiguer Macià, Xavier Matias-Guiu, Sònia Gatius, David Llobet-Navàs, Núria Eritja, Pol Sisó
| Nature Verified
Abstract Loss-of-function mutations in AT-rich interactive domain-containing protein 1 A (ARID1A), accompanied by reduced protein expression, are common in endometrial carcinoma (EC) and correlate with shorter progression-free survival. Alterations in the EC cells secretome play a critical role in shaping the tumor microenvironment (TME), thereby promoting disease progression, metastasis, and therapeutic resistance.
Open in Who Shared Issue with article?

Metabolomic-Based Approaches for Endometrial Cancer Diagnosis and Prognosis: A Review

|
By Anna Borbonet Macià, Sònia Gatius, Manel Albertí-Valls, Cristina Megino-Luque
| MDPI
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Open in Who Shared Issue with article?

Effects of the multikinase inhibitors Sorafenib and Regorafenib in PTEN deficient neoplasias

|
By Cristina Mirantes, Maria Alba Dosil, Núria Eritja, Isidre Felip, Sònia Gatius
| European Journal of Cancer Verified
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. FiguresFig. 1Sorafenib and Regorafenib reduce cell viability in endometrial, thyroid and prostate cancer cell lines. (A) MFE-296, IK, Cal-62, FTC 133 and R’A cells were treated for 48 h with increasing doses of Sorafenib or (B) Regorafenib and cell viability was evaluated by MTT. Results are expressed as percentage of survival over control values.
Open in Who Shared Issue with article?
See all 3 articles